Abbott Japan Gains FDA Approval for New Heart Failure Patient Monitoring Capabilities
What happened
Abbott Japan received U.S. Food and Drug Administration approval for updates to the CardioMEMS HF System. These updates, utilizing the CardioGuide HF App, allow U.S. CardioMEMS patients to view their pulmonary artery pressure readings directly on their smartphones. The CardioMEMS HF System measures pulmonary artery pressure through an implanted sensor in the pulmonary artery.
From dicardiology.com
Why it matters
The CardioMEMS HF System has been shown to reduce heart failure hospitalizations and mortality risk. The new capability allows care teams and patients to monitor signs of worsening heart failure earlier, helping patients take a more active role in managing their condition between office visits.
From dicardiology.com
Who's involved
- Abbott JapanAnnounced the FDA approval for updates to the CardioMEMS HF System.
- Mid America Heart InstituteCollaborated with Abbott Japan on advancing heart failure management technology.
- FDAProvided market authorization and regulatory oversight for Abbott Japan's products.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Mid America Heart InstituteSpeculative
Mid America Heart Institute could see increased demand for specialized heart failure management services due to the adoption of the new technology.
Keep exploring
The entities involved
-
Abbott Japan
Nothing else this week.
-
Mid America Heart Institute
hospital in Kansas City, Missouri
Nothing else this week.
- FDA